News

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.

In the phase 2 FIDES-01 clinical trial, treatment with the FGFR inhibitor, derazantinib, led to an objective response rate of 24% in patients with FGFR2 gene fusion-positive advanced intrahepatic cholangiocarcinoma.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.

After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.

Over the last 10 years, the treatment landscape for biliary tract cancers, specifically intrahepatic cholangiocarcinoma, has evolved and now offers physicians more front- and second-line choices for their patients. For targeted agents in this setting, promising new data have come out for patients with actionable alterations.

The FDA granted Orphan Drug designation to first-in-class LSD1 inhibitor iadademstat, for the treatment of patients with acute myeloid leukemia.

A Biologics License Application was submitted to the FDA for tisotumab vedotin as treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The addition of napabucasin to the FOLFIRI regimen with or without bevacizumab did not demonstrate improvement in overall survival when given as treatment of patients with metastatic colorectal cancer, missing the primary end point of the phase 3 CanStem303C study.

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

The FDA has approved cemiplimab-rwlc, the PD-1 inhibitor, for the treatment of patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog inhibitor is not appropriate.

The FDA granted Breakthrough Therapy Designation to the novel STAMP inhibitor asciminib for 2 populations of patients with Philadelphia chromosome-positive chronic myeloid leukemia.

As the population ages and the rate of cancer screenings fall due to the coronavirus disease 2019 pandemic, the lack of rural oncologists underscores the need for advanced practitioners.

The FDA has granted Orphan Drug Designation to the small-molecule tyrosine kinase inhibitor apatinib for the treatment of the rare malignancy, adenoid cystic carcinoma.

During a Targeted Oncology Case-Based Peer Perspectives virtual event, Lee Schwartzberg, MD, medical oncologist, West Cancer Center and Research Institute, discussed the therapeutic options for a 39-year-old woman with HER2-positive breast cancer who was heavily pretreated.

Good responses to lenvatinib were observed in patients with hepatocellular carcinoma who maintained a high relative dose intensity of 75% or greater.

Delivering the right treatment to the right patient with an eye toward tumor characteristics and gene alterations is at the heart of precision medicine. In this issue, we explore ongoing efforts to achieve precision medicine across disease settings.

The approval of adotrastuzumab emtansine prompted the American Society of Clinical Oncology to issue guidelines regarding the selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer.

Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.

Treatment with single-agent durvalumab did not improve overall survival when compared with the standard-of-care frontline combination of chemotherapy plus cetuximab as treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors highly expressed PD-L1.

The FDA has granted approval to lisocabtagene maraleucel a CD19-targeting chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received at least 2 prior lines of systemic therapy.

The FDA has granted accelerated approval to umbralisib for the treatment of patients with relapsed or refractory marginal zone lymphoma who have received at least 1 prior regimen with anti-CD20 therapy, and for patients with follicular lymphoma who have received at least 2 prior systemic therapies.

A collaborative effort between Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has led to the discovery and validation of the novel Burkitt Lymphoma International Prognostic Index, a model for prognostication of patients with Burkitt lymphoma.

The FDA has granted Fast Track designation to the investigational peptide drug conjugate TH1902 for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

In an interview with Targeted Oncology, Preetesh Jain, MBBS, MD, DM, PhD, assistant professor, reviewed the results seen with ibrutinib added to rituximab in older patients with mantle cell lymphoma and provided insight on how to manage the interesting toxicity profile observed with the combination.

The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive non–small cell lung cancer with acquired RET fusions.

Marcia Brose, MD, PhD discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer.